Is Volumetric Modulated Arc Radiotherapy a Good Choice in the Treatment of Early Glottic Cancer: A Dosimetric Study | ||||
Research in Oncology | ||||
Article 2, Volume 20, Issue 2, December 2024, Page 33-39 PDF (189.66 K) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/resoncol.2024.285976.1209 | ||||
![]() | ||||
Authors | ||||
Rabab A. Abdel Moneim ![]() ![]() ![]() | ||||
1Department of Clinical Oncology and Nuclear Medicine, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt | ||||
2Medical Physics, Department of Clinical Oncology and Nuclear Medicine, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt | ||||
Abstract | ||||
Background: The extended survival of patients with early glottic cancer has heightened concerns about the long-term side effects of radiation therapy, which may negatively impact quality of life and increase the risk of non-malignant mortality. This study evaluated whether volumetric modulated arc radiotherapy (VMAT) offers improved target volume coverage and better protection of organs at risk (OARs) compared to three-dimensional conformal radiotherapy (3D-CRT) in patients with early glottic cancer. Methods: Computed tomography (CT) images from 13 patients with early glottic cancer were analyzed to compare the dosimetric plans of 3D-CRT and VMAT. Dose-volume histogram (DVH) parameters were assessed across 26 treatment plans, including the homogeneity index (HI) and conformity index (CI) for the planning target volume (PTV). Specific dose-volume metrics for OARs, such as the carotid arteries, thyroid gland, and spinal cord, were also compared between the two modalities. Results: VMAT plans demonstrated significantly higher PTV mean dose, PTV maximum dose, and volume receiving 95% of the prescribed dose compared to 3D-CRT plans (p = 0.047, 0.045, and <0.001, respectively). VMAT also showed superior homogeneity and conformity indices for the PTV (p = 0.003 and 0.001, respectively). Additionally, the mean doses to the right and left carotid arteries and the thyroid gland were significantly lower with VMAT (p = 0.009, 0.03, and <0.001, respectively). Conclusion: VMAT provides superior dose-volume parameters for target coverage, homogeneity, and sparing of OARs compared to 3D-CRT in the treatment of early glottic cancer. These advantages suggest that VMAT may be particularly beneficial for patients at increased risk of cerebrovascular complications. | ||||
Keywords | ||||
Early glottic cancer; dosimetric comparison; VMAT; 3D-CRT; carotid sparing | ||||
Statistics Article View: 167 PDF Download: 162 |
||||